NYSEAMERICAN:OCXOncoCyte Stock Price, Forecast & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for OncoCyte.

OncoCyte is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for OncoCyte.

OncoCyte Corp (NYSEAMERICAN:OCX) announced its quarterly earnings data on Tuesday, May, 12th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.02. The biotechnology company earned $0.02 million during the quarter. View OncoCyte's earnings history.

3 brokers have issued twelve-month price targets for OncoCyte's shares. Their forecasts range from $4.00 to $7.75. On average, they expect OncoCyte's stock price to reach $6.25 in the next twelve months. This suggests a possible upside of 135.8% from the stock's current price. View analysts' price targets for OncoCyte.

News coverage about OCX stock has been trending somewhat positive on Thursday, InfoTrie reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. OncoCyte earned a news sentiment score of 1.6 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutOncoCyte.

Some companies that are related to OncoCyte include Bellus Health (BLU), Oxford BioMedica (OXB), CEL-SCI (CVM), Cel-Sci (CVM), SIGA Technologies (SIGA), Paradigm Biopharmaceuticals (PAR), Biotest (BIO), Neptune Wellness Solutions (NEPT), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Starpharma (SPL), ProMetic Life Sciences (PLI), Medicenna Therapeutics (MDNA), IMV (IMV) and Exicure (XCUR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include BioTime (BTX), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Geron (GERN), Anavex Life Sciences (AVXL), Novocure (NVCR), Amicus Therapeutics (FOLD), Genocea Biosciences (GNCA), Inovio Pharmaceuticals (INO) and Ovid Therapeutics (OVID).

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

OncoCyte's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.51%), State Street Corp (0.69%), P.A.W. Capital Corp (0.56%), Geode Capital Management LLC (0.52%), Phoenix Holdings Ltd. (0.39%) and Penbrook Management LLC (0.35%). Company insiders that own OncoCyte stock include Andrew Arno, Biotime Inc, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews and Thomas Alex Vetter. View institutional ownership trends for OncoCyte.

OCX stock was sold by a variety of institutional investors in the last quarter, including Mesirow Financial Investment Management Inc., Morgan Stanley, BlackRock Inc., UBS Group AG, and State Street Corp. View insider buying and selling activity for OncoCyte.

OCX stock was purchased by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd., P.A.W. Capital Corp, Penbrook Management LLC, Nuveen Asset Management LLC, Perkins Capital Management Inc., Geode Capital Management LLC, Bank of New York Mellon Corp, and ETF Managers Group LLC. Company insiders that have bought OncoCyte stock in the last two years include Andrew Arno, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews, and Thomas Alex Vetter. View insider buying and selling activity for OncoCyte.

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OCX stock can currently be purchased for approximately $2.65.

OncoCyte has a market capitalization of $178.13 million. OncoCyte employs 12 workers across the globe.

The official website for OncoCyte is www.oncocyte.com.

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515.